Details of the Drug Combinations

General Information of This Drug (ID: DMJ0936)

Drug Name

PF-03772304 DMJ0936

Synonyms

MTOR inhibitors, Biotica; MTOR inhibitors, Wyeth; PF-04979064; PF-05017255; PF-05168899; WYE-125132; WYE-132; WYE-178; WYE-354; WYE-600; WYE-687; Imidazolo and pyrazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Pfizer; Imidazolopyrimidine derivatives (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer); PI3K/mTOR signalling inhibitors (cancer), Wyeth; Non-rapamycin mTOR/PI3K inhibitors (cancer), Pfizer; 5H-pyrrolo[3,2-d]pyridimine analogs (cancer), Wyeth

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]
------------------------------------------------------------------------------------

Structure

3D Structure is Not Available

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

7 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PF-03772304 + Ruxolitinib	DCCZVUG	Ruxolitinib	T-cell leukemia/lymphoma (Cell Line: ED-40515)	[2]
PF-03772304 + Panobinostat	DC4KEK3	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
PF-03772304 + Marizomib	DCPL9YV	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
PF-03772304 + Idarubicin	DCII6T2	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
PF-03772304 + PF-562271	DCZ9V5Z	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
PF-03772304 + Ibrutinib	DCSYR2F	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
PF-03772304 + Ruxolitinib	DCCRSR2	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.